• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高效液相色谱法检测和分离血浆及尿液中的米托蒽醌及其代谢产物

Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography.

作者信息

Ehninger G, Proksch B, Schiller E

出版信息

J Chromatogr. 1985 Jul 12;342(1):119-27. doi: 10.1016/s0378-4347(00)84494-1.

DOI:10.1016/s0378-4347(00)84494-1
PMID:4044741
Abstract

A high-performance liquid chromatographic method using ion-pair chromatography on reversed-phase C18 material was developed. After sample clean-up on XAD columns, mitoxantrone at concentrations below 1 ng/ml in serum and 0.2 ng/ml in urine were measurable with a coefficient of variation of less than 9.3% at a wavelength of 658 nm. Four metabolites were separated in urine. The two major metabolites co-chromatographed with the synthesized mono- and dicarboxylic acid derivatives of mitoxantrone. The method allowed the measurement of mitoxantrone and its metabolites in serum up to more than one week and in urine up to four weeks after administration of the drug.

摘要

开发了一种在反相C18材料上使用离子对色谱的高效液相色谱方法。在XAD柱上对样品进行净化后,在波长658nm处,血清中米托蒽醌浓度低于1ng/ml、尿液中低于0.2ng/ml时可被检测到,变异系数小于9.3%。在尿液中分离出了四种代谢物。两种主要代谢物与米托蒽醌合成的单羧酸和二羧酸衍生物共色谱。该方法能够在给药后长达一周以上的时间内测定血清中的米托蒽醌及其代谢物,在给药后长达四周的时间内测定尿液中的米托蒽醌及其代谢物。

相似文献

1
Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography.高效液相色谱法检测和分离血浆及尿液中的米托蒽醌及其代谢产物
J Chromatogr. 1985 Jul 12;342(1):119-27. doi: 10.1016/s0378-4347(00)84494-1.
2
The pharmacokinetics and metabolism of mitoxantrone in man.米托蒽醌在人体内的药代动力学和代谢
Invest New Drugs. 1985;3(2):109-16. doi: 10.1007/BF00174157.
3
Detection and separation of the anthrapyrazole CI-941 and its metabolites in serum and urine by high-performance liquid chromatography.
J Chromatogr B Biomed Appl. 1994 Aug 19;658(2):349-53. doi: 10.1016/0378-4347(94)00235-5.
4
Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone.新型抗肿瘤药物双胺苯吖啶和米托蒽醌的高效液相色谱法改进
J Chromatogr. 1982 Dec 10;233:235-47. doi: 10.1016/s0378-4347(00)81750-8.
5
Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography.通过固相萃取和高效液相色谱法测定血浆和尿液中的蒽吡唑类抗癌药物CI-941。
J Chromatogr. 1989 Jun 30;491(1):253-61. doi: 10.1016/s0378-4347(00)82841-8.
6
Ion-paired high-performance liquid chromatographic determination of mitoxantrone in physiological fluids.离子对高效液相色谱法测定生理体液中的米托蒽醌
J Chromatogr. 1985 Jan 11;337(1):73-80. doi: 10.1016/0378-4347(85)80009-8.
7
Identification of human urinary mitoxantrone metabolites.
Cancer Res. 1986 Sep;46(9):4858-61.
8
Direct determination of mitoxantrone and its mono- and dicarboxylic metabolites in plasma and urine by high-performance liquid chromatography.通过高效液相色谱法直接测定血浆和尿液中的米托蒽醌及其单羧酸和二羧酸代谢物。
J Chromatogr. 1988 Feb 26;424(2):337-45. doi: 10.1016/s0378-4347(00)81110-x.
9
Detection and identification of human urinary metabolites of biantrazole (CI-941).
Drug Metab Dispos. 1993 Sep-Oct;21(5):955-61.
10
Disposition of mitoxantrone in cancer patients.米托蒽醌在癌症患者体内的处置情况。
Cancer Res. 1985 Apr;45(4):1879-84.

引用本文的文献

1
Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.
Cancer Chemother Pharmacol. 1995;37(1-2):103-9. doi: 10.1007/BF00685636.
2
Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells.米托蒽醌与阿霉素对人粒细胞-巨噬细胞祖细胞的体外毒性比较
Cancer Chemother Pharmacol. 1987;20(1):8-12. doi: 10.1007/BF00252951.
3
Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?还原型醌类必然参与醌类药物的抗肿瘤活性吗?
Br J Cancer Suppl. 1987 Jun;8:53-9.
4
Pharmacokinetics and metabolism of mitoxantrone. A review.
Clin Pharmacokinet. 1990 May;18(5):365-80. doi: 10.2165/00003088-199018050-00003.
5
Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.米托蒽醌在接受大剂量化疗和自体骨髓移植治疗的癌症患者中的药代动力学。
Br J Cancer. 1992 Mar;65(3):399-404. doi: 10.1038/bjc.1992.81.